Clinical significance of the measurements of plasma N-terminal pro-B-type natriuretic peptide levels in patients with coronary artery disease who have undergone elective drug-eluting stent implantation

Journal of Cardiology

Volumn 57, Issue 3, 2011, Pages 303-310

  Masaki, Yoshiyuki ^a   Shimada, Kazunori ^a   Kojima, Takahiko ^a   Miyauchi, Katsumi ^a   Inoue, Kenji ^a   Kiyanagi, Takashi ^a   Hiki, Makoto ^a   Fukao, Kosuke ^a   Hirose, Kuniaki ^a   Ohsaka, Hiromichi ^a   Kume, Atsumi ^a   Miyazaki, Tetsuro ^a   Ohmura, Hirotoshi ^a   Ohsaka, Akimichi ^a   Daida, Hiroyuki ^a  

^a JUNTENDO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Cardiovascular events; Coronary artery disease; Drug eluting stent; N terminal pro B type natriuretic peptide

Indexed keywords

ACETYLSALICYLIC ACID; AMINO TERMINAL PRO BRAIN NATRIURETIC PEPTIDE; BIOLOGICAL MARKER; CLOPIDOGREL; GLYCERYL TRINITRATE; HEMOGLOBIN A1C; HEPARIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; TICLOPIDINE;

ADULT; ANGIOCARDIOGRAPHY; ANTICOAGULANT THERAPY; ARTICLE; BODY MASS; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; CORONARY ARTERY BYPASS GRAFT; CORONARY ARTERY DISEASE; CORONARY STENT; DEATH; DIABETES MELLITUS; DISEASE FREE SURVIVAL; DRUG ELUTING STENT; ELECTIVE SURGERY; FEMALE; FOLLOW UP; HEART INFARCTION; HEMOGLOBIN BLOOD LEVEL; HUMAN; HYPERTENSION; IMMUNOASSAY; MAJOR CLINICAL STUDY; MALE; PERCUTANEOUS CORONARY INTERVENTION; PREDICTOR VARIABLE; PROTEIN BLOOD LEVEL; REFERENCE VALUE; RISK FACTOR; STROKE; UNSTABLE ANGINA PECTORIS;

BIOLOGICAL MARKERS; CORONARY ANGIOGRAPHY; CORONARY ARTERY DISEASE; DRUG-ELUTING STENTS; FEMALE; FOLLOW-UP STUDIES; HEART FAILURE; HUMANS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; NATRIURETIC PEPTIDE, BRAIN; PEPTIDE FRAGMENTS;

EID: 79955026582     PISSN: 09145087     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jjcc.2011.01.015     Document Type: Article

References (21)

1. Tang W.H., Francis G.S., Morrow D.A., Newby L.K., Cannon C.P., Jesse R.L., Storrow A.B., Christenson R.H., Apple F.S., Ravkilde J., Wu A.H., National Academy of Clinical Biochemistry Laboratory Medicine National Academy of Clinical Biochemistry Laboratory Medicine practice guidelines: clinical utilization of cardiac biomarker testing in heart failure. Circulation 2007, 116:e99-e109.
2. Januzzi J.L., Camargo C.A., Anwaruddin S., Baggish A.L., Chen A.A., Krauser D.G., Tung R., Cameron R., Nagurney J.T., Chae C.U., Lloyd-Jones D.M., Brown D.F., Foran-Melanson S., Sluss P.M., Lee-Lewandrowski E., et al. The N-terminal Pro-BNP investigation of dyspnea in the emergency department (PRIDE) study. Am J Cardiol 2005, 95:948-954.
3. Yamashita T., Seino Y., Ogawa A., Ogata K.-i., Fukushima M., Tanaka K., Mizuno K. N-terminal pro-BNP is a novel biomarker for integrated cardio-renal burden and early risk stratification in patients admitted for cardiac emergency. J Cardiol 2010, 55:377-383.
4. Mair J., Hammerer-Lercher A., Puschendorf B. The impact of cardiac natriuretic peptide determination on the diagnosis and management of heart failure. Clin Chem Lab Med 2001, 39:571-588.
5. Hildebrandt P., Collinson P.O. Amino-terminal pro-B-type natriuretic peptide testing to assist the diagnostic evaluation of heart failure in symptomatic primary care patients. Am J Cardiol 2008, 101:25-28.
6. Masson S., Latini R., Anand I.S., Vago T., Angelici L., Barlera S., Missov E.D., Clerico A., Tognoni G., Cohn J.N., Val-HeFT Investigators Direct comparison of B-type natriuretic peptide (BNP) and amino-terminal proBNP in a large population of patients with chronic and symptomatic heart failure: the Valsartan Heart Failure (Val-HeFT) data. Clin Chem 2006, 52:1528-1538.
7. Kragelund C., Grønning B., Køber L., Hildebrandt P., Steffensen R. N-terminal pro-B-type natriuretic peptide and long-term mortality in stable coronary heart disease. N Engl J Med 2005, 352:666-675.
8. McAlister F.A., Ezekowitz J., Tonelli M., Armstrong P.W. Renal insufficiency and heart failure: prognostic and therapeutic implications from a prospective cohort study. Circulation 2004, 109:1004-1009.
9. Weber M., Dill T., Arnold R., Rau M., Ekinci O., Müller K.D., Berkovitsch A., Mitrovic V., Hamm C. N-terminal B-type natriuretic peptide predicts extent of coronary artery disease and ischemia in patients with stable angina pectoris. Am Heart J 2004, 148:612-620.
10. Bibbins-Domingo K., Gupta R., Na B., Wu A.H., Schiller N.B., Whooley M.A. N-terminal fragment of the prohormone brain-type natriuretic peptide (NT-proBNP), cardiovascular events, and mortality in patients with stable coronary heart disease. JAMA 2007, 297:169-176.
11. Moses J.W., Leon M.B., Popma J.J., Fitzgerald P.J., Holmes D.R., O'Shaughnessy C., Caputo R.P., Kereiakes D.J., Williams D.O., Teirstein P.S., Jaeger J.L., Kuntz R.E., SIRIUS Investigators Sirolimus-eluting stents versus standard stents in patients with stenosis in a native coronary artery. N Engl J Med 2003, 349:1315-1323.
12. Imai E., Horio M., Watanabe T., Iseki K., Yamagata K., Hara S., Ura N., Kiyohara Y., Moriyama T., Ando Y., Fujimoto S., Konta T., Yokoyama H., Makino H., Hishida A., et al. Prevalence of chronic kidney disease in the Japanese general population. Clin Exp Nephrol 2009, 13:621-630.
13. Tschöpe C., Kasner M., Westermann D., Gaub R., Poller W.C., Schultheiss H.P. The role of NT-proBNP in the diagnostics of isolated diastolic dysfunction: correlation with echocardiographic and invasive measurements. Eur Heart J 2005, 26:2277-2284.
14. Martinez-Rumayor A., Richards A.M., Burnett J.C., Januzzi J.L. Biology of the natriuretic peptides. Am J Cardiol 2008, 101:3-8.
15. de Lemos J.A., McGuire D.K., Drazner M.H. B-type natriuretic peptide in cardiovascular disease. Lancet 2003, 362:316-322.
16. Burnett J.C. Novel therapeutic directions for the natriuretic peptides in cardiovascular diseases: what's on the horizon. J Cardiol 2006, 48:235-241.
17. Weber M., Hamm C. Role of B-type natriuretic peptide (BNP) and NT-proBNP in clinical routine. Heart 2006, 92:843-849.
18. Anwaruddin S., Lloyd-Jones D.M., Baggish A., Chen A., Krauser D., Tung R., Chae C., Januzzi J.L. Renal function, congestive heart failure, and amino-terminal pro-brain natriuretic peptide measurement: results from the ProBNP Investigation of Dyspnea in the Emergency Department (PRIDE) Study. J Am Coll Cardiol 2006, 47:91-97.
19. Bibbins-Domingo K., Ansari M., Schiller N.B., Massie B., Whooley M.A. B-type natriuretic peptide and ischemia in patients with stable coronary disease: data from the Heart and Soul study. Circulation 2003, 108:2987-2992.
20. Ahluwalia A., MacAllister R.J., Hobbs A.J. Vascular actions of natriuretic peptides Cyclic GMP-dependent and -independent mechanisms. Basic Res Cardiol 2004, 99:83-89.
21. Omland T., Sabatine M.S., Jablonski K.A., Rice M.M., Hsia J., Wergeland R., Landaas S., Rouleau J.L., Domanski M.J., Hall C., Pfeffer M.A., Braunwald E., PEACE Investigators Prognostic value of B-type natriuretic peptides in patients with stable coronary artery disease: the PEACE Trial. J Am Coll Cardiol 2007, 50:205-214.